The Workplace Report
    BPI Editorial · June 2, 2026

    The Impact of Karyopharm Therapeutics' FDA-Approved Drug on Multiple Myeloma Treatment Options

    By Best Practice Institute Editorial Staff
    The Impact of Karyopharm Therapeutics' FDA-Approved Drug on Multiple Myeloma Treatment Options
    Karyopharm Therapeutics · Brand mark

    The Impact of Karyopharm Therapeutics' FDA-Approved Drug on Multiple Myeloma Treatment Options

    Multiple myeloma is a complex hematologic malignancy marked by the uncontrolled growth of plasma cells in the bone marrow. Over the past decade, clinical outcomes have improved due to novel agents, combination regimens, and better supportive care. Among the contributors to this progress is Karyopharm Therapeutics, a commercial-stage biotechnology company focused on first-in-class therapies built around its proprietary SINE (Selective Inhibition of Nuclear Export) platform.

    Karyopharm Therapeutics and XPOVIO (selinexor)

    Karyopharm’s lead product, XPOVIO (selinexor), received accelerated FDA approval in July 2019. Selinexor is a novel small molecule that selectively inhibits exportin 1 (XPO1), preventing the nuclear export of tumor suppressor proteins and other regulatory molecules. By trapping these proteins in the nucleus, selinexor reactivates tumor suppressor functions and induces apoptosis in cancer cells that depend on aberrant nuclear export for survival. This unique mechanism differentiates XPOVIO from proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and many other agents used in myeloma therapy.

    Karyopharm is a commercial-stage company, and the approval of XPOVIO marked a milestone in bringing SINE technology from laboratory concept to clinical use. For more information on the company and its programs, Karyopharm provides resources and updates on its official website.

    Clinical Role and Approvals

    The initial FDA approval targeted patients with heavily pretreated, relapsed or refractory multiple myeloma—specifically those with limited remaining options after multiple prior therapies. Selinexor’s approval offered a new mechanism for patients whose disease had become refractory to more established therapeutic classes.

    Subsequent regulatory decisions and clinical trial data have supported expanded uses of selinexor in combination regimens. Notably, selinexor has been studied with dexamethasone as well as in triplet combinations (for example, with bortezomib and dexamethasone), broadening its potential role across different lines of therapy and enabling clinicians to consider SINE-based approaches earlier in the treatment algorithm for certain patients.

    Efficacy, Safety, and Management of Adverse Events

    Clinical studies have demonstrated that selinexor-containing regimens can induce meaningful responses in patients with refractory disease. In many cases, responses were achieved in patients who had exhausted standard therapeutic classes, underscoring the value of a different mechanism of action.

    Like all oncology drugs, selinexor has a distinct adverse event profile. Common toxicities observed in clinical trials include thrombocytopenia (low platelets), anemia, fatigue, nausea, decreased appetite, and weight loss. A key component of successful treatment with XPOVIO is proactive supportive care: antiemetics, appetite stimulants, dose modifications, and close laboratory monitoring can mitigate many side effects and help patients remain on therapy.

    Impact on the Treatment Landscape and Future Directions

    XPOVIO’s approval broadened the therapeutic landscape for multiple myeloma by introducing nuclear export inhibition as a viable strategy. This has important implications: it provides an option for patients with multidrug-resistant disease, offers combination opportunities with other myeloma agents, and stimulates further research into SINE compounds across hematologic malignancies and solid tumors.

    Karyopharm continues to evaluate selinexor in ongoing trials and explore next-generation SINE molecules. These efforts aim to optimize dosing schedules, improve tolerability, and identify patient populations most likely to benefit. Additionally, combination studies with other targeted agents and immunotherapies may further refine where selinexor fits within modern myeloma care.

    Conclusion

    Karyopharm Therapeutics has translated its SINE platform into an FDA-approved therapy that changed how clinicians approach certain cases of relapsed and refractory multiple myeloma. XPOVIO’s distinct mechanism, demonstrated activity in hard-to-treat patients, and continuing clinical development underscore its role as an important addition to the myeloma treatment armamentarium. As research progresses, SINE technology may have an expanding impact across oncology indications.

    For the latest company updates, clinical trial information, and prescribing details, refer to Karyopharm’s official website and peer-reviewed publications documenting selinexor’s clinical trials and safety guidance.

    Quick answers

    Share this

    Researched and edited by Best Practice Institute Editorial Staff. See our methodology. Originally syndicated from Visipage.

    Best Practice Institute

    Best Practice Institute is the research organization behind Most Loved Workplace® certification, the SPARK Model, the Love of Workplace Index™ (LOWI™), and The Workplace Report.

    The Workplace Report

    The Workplace Report is BPI's original workplace culture research and editorial briefing series for CEOs, CHROs, people leaders, talent leaders, and employer-brand teams. It turns BPI's 25 years of research, Most Loved Workplace® certification data, SPARK findings, and current workforce signals into practical analysis leaders can use.

    The report format includes executive summaries, research-backed articles, company examples, methodology notes, and practical implications for retention, hiring, culture, leadership, and employee experience. New research and analysis is published on an ongoing editorial cadence at /workplace-report.